Issam Awad to Administration, Oral
This is a "connection" page, showing publications Issam Awad has written about Administration, Oral.
Connection Strength
0.085
-
Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial. CNS Drugs. 2025 Sep; 39(9):865-877.
Score: 0.051
-
A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. Transl Stroke Res. 2020 06; 11(3):365-376.
Score: 0.034